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OBJECTIVES We sought to develop a model based on information available from the medical record that
would accurately stratify elderly patients who survive hospitalization with an acute myocardial
infarction (AMI) according to their risk of one-year mortality.
BACKGROUND Prediction of the risk of mortality among older survivors of an AMI has many uses, yet few
studies have determined the prognostic importance of demographic, clinical and functional
data that are available on discharge in a population-based sample.
METHODS In a cohort of patients aged $65 years who survived hospitalization for a confirmed AMI
from 1994 to 1995 at acute care, nongovernmental hospitals in the U.S., we developed a
parsimonious model to stratify patients by their risk of one-year mortality.
RESULTS The study sample of 103,164 patients, with a mean age of 76.8 years, had a one-year mortality
of 22%. The factors with the strongest association with mortality were older age, urinary
incontinence, assisted mobility, presence of heart failure or cardiomegaly any time before
discharge, presence of peripheral vascular disease, body mass index ,20 kg/m2, renal
dysfunction (defined as creatinine .2.5 mg/dl or blood urea nitrogen .40 mg/dl) and left
ventricular dysfunction (left ventricular ejection fraction ,40%). On the basis of the
coefficients in the model, patients were stratified into risk groups ranging from 7% to 49%.
CONCLUSIONS We demonstrate that a simple risk model can stratify older patients well by their risk of death
one year after discharge for AMI. (J Am Coll Cardiol 2001;38:453–9) © 2001 by the
American College of Cardiology
Previous studies of prognosis among survivors of acute
myocardial infarction (AMI) have not always been relevant
See page 460
to older patients, a group that represents the majority of
those seen in practice (1). Some studies have focused on
invasive or noninvasive test results that are not available or
appropriate for all patients (2–7). Others have used popu-
lations from referral centers or patients who were part of
clinical trials or epidemiologic studies from specific geo-
graphic regions (8,9). None of the studies have focused
specifically on older patients. As a result, little information
is available about the prognostic importance of comorbidity
in addition to measures of disease severity for elderly
patients after AMI.
Accordingly, we sought to study the one-year prognosis
of a national sample of older patients who survived hospi-
talization for an AMI. The objective of this study was to
develop a parsimonious model to predict mortality based on
information that is available in the medical record. We
particularly sought to identify the strongest factors that were
independently associated with one-year survival. This study
was conducted as part of the Cooperative Cardiovascular
Project (CCP), a Health Care Financing Administration
initiative to improve the quality of care for Medicare
beneficiaries with an AMI.
METHODS
Data sources. The CCP database has been described
previously (10). In brief, it includes more than 200,000
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patients hospitalized across the country with a principal
discharge diagnosis of AMI (International Classification of
Diseases, Ninth Revision, Clinical Modification [ICD-9-
CM] 410) from 1994 to 1995. The Medicare Enrollment
Database was the source for the vital status of the Medicare
beneficiaries in this study (11).
Study sample. The overall study sample was restricted to
patients who were aged $65 years, who had a confirmed
AMI as previously reported (10), who were not received in
transfer from another institution or not transferred out to
another acute-care hospital and who survived the index
hospitalization. To avoid counting patients more than once,
we included only a patient’s first confirmed AMI hospital-
ization.
Candidate predictor variables. On the basis of medical
literature review and clinical experience, we selected candi-
date predictor variables that described demographic and
clinical characteristics of the patients. These variables are
shown in Table 1.
Left ventricular ejection fraction (LVEF) levels were
measured using one of the following three methods: radio-
nuclide ventriculography, echocardiogram or cardiac cathe-
terization. For patients in whom LVEF was measured using
more than one method, we selected one measurement,
prioritized in descending order as listed in the preceding
text. The LVEF levels were grouped into four categories:
,20%, 20% to 39%, 40% to 54%, and $55%. Qualitative
measures of left ventricular function were translated into
quantitative measures as follows: normal left ventricular
function was assigned a value of $55%, mild or mild-
moderate depression 40% to 54%, moderate or moderate-
severe depression 20% to 39% and severe depression ,20%.
Missing data and extreme values. In general, missing data
were considered characteristics not present for dichotomous
or categorical variables. For continuous variables, a dummy
variable was created to indicate missing values and was
forced in the model when the corresponding variable was
being analyzed. To guard against influential observations,
we treated implausible recorded values for continuous vari-
ables as missing. If the recorded values were outside of the
following ranges, we recorded the values as missing: respi-
ratory rate 0 to 80 breaths/min, systolic blood pressure 0 to
300 mm Hg, diastolic blood pressure 0 to 150 mm Hg,
serum urea nitrogen 5 to 150 mg/dl, creatinine and highest
creatinine 0.1 to 15 mg/dl, albumin 2 to 20 mg/dl, hemat-
ocrit 10% to 65%, white blood cell count 3,000 to 50,000
and body mass index 0 to 50 kg/m2.
Few missing values (,2%) occurred in the majority of the
candidate predictors. Missing observations exceeded 5% for
only the following candidate predictor variables: AMI
symptoms within 48 h before admission (15%), time since
chest pain started (9%), body mass index (15%), albumin
(27%) and LVEF (30%).
Model development. We defined a derivation sample for
model development that randomly included half the pa-
tients in the study sample. In this derivation set, we
evaluated by visual inspection the association of the contin-
uous variables with the outcome to check for assumptions of
linearity. We identified cutpoints using clinical judgment
and knowledge of these relationships.
We performed iterations of Cox regression models with
survival days from discharge as the dependent variable and
censored by one-year mortality from discharge, gradually
reducing the number of independent predictors. We began
with all candidate predictors (except procedures and medi-
cations because these factors might be susceptible to inten-
tional manipulation) with their associated dummy variables
and a stepwise method with an entry level of p , 0.0005
and an exit level of p . 0.0001. When variables with
missing observations were included in or removed from
multivariate models, dummy variables indicating the pres-
ence of missing values (yes/no) were also added or removed.
In order to identify the most influential variables, the model
was further restricted to variables with a Wald chi-square
value of .50. We created composite variables where related
variables with similar odds ratios and clinical information
(e.g., blood urea nitrogen .40 mg/dl and highest creatinine
.2.5 mg/dl) were combined. We then repeated the Cox
regression model to select variables with a Wald chi-square
value of .100. Although this threshold is arbitrary, it
allowed for the selection of variables with strong clinical
associations to one-year mortality. Finally, we added cardiac
procedures/treatments during hospitalization and discharge
prescription of aspirin and beta-blockers to the final model
to examine the stability of the selected risk predictors.
Model evaluation and validation. To identify potential
problematic areas of model fit, we constructed and exam-
ined partial residual plots (12) using the derivation sample.
We then did the logistic regression analysis (with one-year
mortality as the dependent variable and the variables in the
derived Cox model as independent variables) to construct
the receiver operating characteristic (ROC) curves (13) and
to calculate the area under them. In general, an area under
the ROC curves (AROC) .0.75 is considered to have good
discriminant ability. We also evaluated the calibration of the
model, or the extent to which the predicted probabilities are
similar to what is observed, using the Hosmer-Lemeshow
chi-square statistic. We repeated this evaluation in the
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
AROC 5 area under the receiver operating
characteristic
CCP 5 Cooperative Cardiovascular Project
GUSTO 5 Global Utilization of Streptokinase and
tPA for Occluded Coronary Arteries
ICD-9-CM 5 International Classification of Diseases,
Ninth Revision, Clinical Modification
LVEF 5 left ventricular ejection fraction
PREDICT 5 Predicting Risk of Death in Cardiac
Disease Tool
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validation set. Lastly, we stratified patients into 10 groups
based on ranking of their predicted mortality, then com-
pared the observed mortality rate and predicted mortality
rate among these groups in the validation cohort.
Risk score and risk category. On the basis of the final risk
prediction model, we assigned a weight to each risk factor
by dividing its coefficient estimate by the smallest coefficient
among all of the variables that were estimated in the model.
A risk score was then calculated for each patient by
multiplying the weight to the presence or absence of the
corresponding risk factor. A patient’s risk of dying within
one year postdischarge was further categorized as low,
medium or high according to his/her risk score. The
association between risk categories and one-year mortality
was assessed with the use of the Cochran-Armitage test for
trend in the validation cohort. To determine the generaliz-
ability of the identified predictors, we also examined the
association of this risk prediction rule with all-cause read-
mission or death combined and AMI-specific readmission
or death combined.
RESULTS
Study sample. Table 2 presents the inclusion and exclusion
criteria of the study sample. The final study sample included
103,164 patients and was randomly split to include 51,851
patients in the derivation cohort and 51,313 patients in the
validation cohort.
Predictors of one-year mortality. Table 1 presents the
bivariate analysis between selected candidate predictors and
one-year mortality in the derivation cohort. Among all
candidate predictors examined, eight were identified, based
on Cox proportional hazard regression models, to be asso-
ciated with significantly increased risk of one-year mortality
and, thus, were included in the final model as shown (Table
3). These factors were older age, urinary incontinence,
assisted mobility, presence of heart failure or cardiomegaly
any time before discharge, presence of peripheral vascular
disease, body mass index ,20 kg/m2, renal dysfunction
(defined as creatinine .2.5 mg/dl or blood urea nitrogen
.40 mg/dl) and left ventricular dysfunction (LVEF
,40%). Adding aspirin and beta-blocker prescription at
discharge and cardiac procedures during hospitalization did
not change the predictive significance of these clinical
characteristics.
Model performance and model validation. In a logistic
regression model with all of the candidate predictors (except
the medications and procedures), the AROC was 0.80; in
the logistic regression model with selected predictors for the
final model, the AROC was 0.77, indicating good model
discrimination. Beyond the eight variables that were se-
lected for the model, the next three strongest measures were
hypertension (systolic blood pressure .180 mm Hg or
diastolic blood pressure .110 mm Hg), dementia and
diabetes, with Wald chi-square values of 94, 73 and 63,
respectively. If these variables were added to the model, the
AROC increased by 0.004. In the analysis of subgroups
without LVEF missing values or without body mass index
missing values, the corresponding logistic regression models
with the selected predictors in the final model did not
change appreciably and still had an AROC of 0.77, indi-
cating good model discrimination.
There was no evidence of a lack of fit of the model.
Similar performance of the model was found in the valida-
tion cohort. When we stratified patients into 10 groups
according to their ranks of predicted mortality rate, the
correlation coefficient between the predicted mortality rate
and the observed mortality rate among these groups was
0.997, and the test for equality of the predicted mortality
rate and the observed mortality rate indicated good corre-
lation (p 5 0.553).
Risk score and risk category. Based on estimates in the
final prediction Cox regression model shown in Table 3, the
following weight was assigned to each risk factor: 1—pres-
ence of peripheral vascular disease, age 75 to 84 years, body
mass index ,20 kg/m2, urinary incontinence or no urinary
output, and walks with assistance; 2—age $85 years, LVEF
20% to 40%, presence of heart failure or cardiomegaly any
time before discharge, renal dysfunction, and inability to
walk; 3—LVEF ,20%.
A risk score was calculated for each patient. The risk
scores ranged from 0 to 13. We further grouped the risk
scores into three categories: 0 to 2 (low risk), 3 to 5
(medium risk) and $6 (high risk). Distribution of the
number of patients and percent mortality in each risk
category is shown in Table 4 for both the derivation and
validation cohorts. About 40% of the cohort was assigned to
the low-risk group and 18% to the high-risk group. As
expected, there was a strong correlation between a higher
risk score and a greater risk of mortality (Cochran-Armitage
trend test p , 0.001). The distributions and the trends were
similar in the derivation and validation cohorts. Patients in
the low-risk category had a 7% one-year mortality rate,
whereas patients in the high-risk category had a 49%
one-year mortality rate. These risk predictors also provide a
stratification of risk for mortality and readmission com-
bined, and readmission and mortality from AMI (Table 4).
DISCUSSION
In this study we developed and validated a simple risk model
for one-year mortality for older individuals who survived
hospitalization for an AMI. The variables are based on
clinical information and the results of an assessment of left
ventricular systolic function available at discharge. Using
this approach, we identified three risk groups with one-year
mortality rates ranging from 7% to 49%.
Previous studies. This study has some important contrasts
with the recently published study of one-year mortality
among the subjects in the Global Utilization of Streptoki-
nase and tPA for Occluded Coronary Arteries (GUSTO)
trial who survived 30 days (14). The GUSTO trial, by
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Table 1. Bivariate Analysis: Characteristics and One-Year Mortality
Characteristics
Survived (40,624) Died (11,227)
N % N % Chi-Square p Value
Demographics
Age, yrs
75–84 15,861 39% 4,924 44% 84.9 0.001
$85 5,495 14% 3,388 30% 1,717.8 0.001
Female 19,874 49% 6,000 53% 71.9 0.001
Non-white 4,195 10% 1,218 11% 2.6 0.109
Medical history
Angina 18,550 46% 5,099 45% 0.2 0.644
Hypertension 25,449 63% 7,098 63% 1.3 0.263
Diabetes (any type) 11,657 29% 4,167 37% 294.2 0.001
Active ulcer disease 5,463 13% 1,484 13% 0.4 0.527
Bleeding disorder 205 1% 67 1% 1.4 0.232
Internal bleeding 3,226 8% 1,130 10% 51.6 0.001
Bypass surgery 5,248 13% 1,435 13% 0.1 0.702
Heart failure or pulmonary edema 6,844 17% 4,583 41% 2,942.5 0.001
Chronic obstructive pulmonary disease 7,816 19% 2,911 26% 239.8 0.001
Cigarette smoker 6,239 15% 1,352 12% 77.4 0.001
Stroke 5,121 13% 2,321 21% 465.7 0.001
Acute myocardial infarction 12,561 31% 4,448 40% 301.9 0.001
Angioplasty 3,049 8% 551 5% 91.9 0.001
Trauma in last month 1,255 3% 545 5% 81.6 0.001
Functional status at discharge
Urinary continence
Incontinent 6,403 8% 5,387 24% 2,352.4 0.001
No urinary output 234 0% 257 1% 110.9 0.001
Mobility
Walks with assistance 18,569 23% 8,937 40% 1,287.4 0.001
Unable to walk 2,507 3% 2,747 12% 1,515.9 0.001
Dementia/Alzheimer’s disease 1,854 5% 1,523 14% 1,170.6 0.001
Clinical presentation and severity variables
Admission blood pressure (mm Hg)
SBP ,160 and DBP ,100 1,859 5% 764 7% 90.1 0.001
(SBP $140 or DBP $90) and SBP ,160 and DBP ,100 2 0% 0% 0.6 0.457
(SBP $160 or DBP $100) and SBP ,180 and DBP ,110 30,839 76% 8,662 77% 7.5 0.006
SBP $180 or DBP $110 7,831 19% 1,774 16% 70.4 0.001
Admission heart rate
,60 beats/min 3,864 10% 526 5% 264.4 0.001
.100 beats/min 8,991 22% 4,273 38% 1,172.2 0.001
Admission respiratory rate .22 breaths/minute 11,990 30% 5,414 48% 1,380.6 0.001
Admission temperature .100.4° 673 2% 333 3% 79.3 0.001
AMI symptoms
Chest pain before admission 35,414 99% 8,246 99% 60.9 0.001
Chest pain prolonged .6 h 14,260 39% 5,151 52% 555.7 0.001
Angina $60 min after arrival 15,412 38% 3,057 27% 439.9 0.001
Hemorrhage (any type) 1,010 2% 473 4% 94.4 0.001
Cardiac arrest 735 2% 232 2% 3.2 0.075
Shock 396 1% 170 2% 23.7 0.001
Gallop rhythm or S3 1,376 3% 741 7% 231.9 0.001
Rales 12,386 30% 5,920 53% 1,904.9 0.001
Heart failure/pulmonary edema 18,432 45% 8,014 71% 2,381.1 0.001
Peripheral vascular disease 3,709 9% 1,734 15% 373.3 0.001
Body mass index
Missing 5,378 13% 2,465 22% 520.7 0.001
.20 kg/m2 32,774 81% 7,459 66% 1,025.7 0.001
Initial laboratory results
Albumin
Missing 11,115 27% 3,008 27% 1.4 0.231
.3 mg/dl 1,153 3% 680 6% 267.2 0.001
BUN .40 mg/dl or creatinine .2.5 mg/dl 2,323 6% 2,269 20% 1,489.8 0.001
Hematocrit ,36% 6,831 17% 3,345 30% 939.4 0.001
Sodium ,130 mmol/l 882 2% 413 4% 82.1 0.001
WBC .12,000/cu mm 9,803 24% 4,093 36% 681.2 0.001
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definition, focused only on persons who were eligible for
and received thrombolytic therapy, whereas our study in-
cluded all older patients hospitalized during the study
period. The marked difference in the population was re-
flected in the outcomes. The one-year mortality rate among
30-day survivors in the GUSTO trial was 2.9% compared
Table 1. Continued
Characteristics
Survived (40,624) Died (11,227)
N % N % Chi-Square p Value
First electrocardiogram
LBBB 2,213 5% 1,198 11% 390.5 0.001
Pacemaker rhythm 567 1% 281 3% 67.0 0.001
RBBB 2,758 7% 1,009 9% 63.1 0.001
ST-segment elevation 11,588 29% 2,717 24% 82.3 0.001
Ventricular tachycardia 240 1% 115 1% 24.3 0.001
Atrial fibrillation/flutter 3,312 8% 1,561 14% 341.7 0.001
2nd/3rd degree heart block 464 1% 138 1% 0.6 0.446
Evidence of old myocardial infarction 2,224 5% 780 7% 35.0 0.001
Documented location(s) of myocardial infarction
Antero/septal 17,870 44% 5,377 48% 54.2 0.001
Subendocardial (non–Q-wave) 16,820 41% 5,197 46% 86.0 0.001
Other 24,495 60% 5,802 52% 269.0 0.001
Hospital events
Highest creatinine .2.5 mg/dl 2,201 5% 1,848 16% 1,489.8 0.001
Pneumonia 2,876 7% 1,694 15% 702.0 0.001
Decubitus ulcers 677 2% 739 7% 800.2 0.001
Deep vein thrombosis 175 0% 76 1% 11.1 0.001
Cerebrovascular accident 793 2% 472 4% 187.4 0.001
Hypotension 7,157 18% 2,115 19% 8.9 0.003
Bradycardia 14,925 37% 2,816 25% 531.0 0.001
Shock 942 2% 366 3% 31.7 0.001
Re-infarction 1,046 3% 316 3% 2.0 0.160
CHF/pulmonary edema 14,674 36% 7,229 64% 2,880.8 0.001
Re-angina 23,465 58% 5,452 49% 301.8 0.001
Hemorrhage/bleeding (any type) 6,621 16% 2,029 18% 19.9 0.001
Hospital medications
ACE inhibitor 16,100 40% 5,914 53% 612.7 0.001
Warfarin 7,215 18% 2,198 20% 19.6 0.001
Heparin .4,000 U 28,699 71% 6,300 56% 846.6 0.001
Thrombolytics 7,005 17% 744 7% 780.0 0.001
Aspirin 34,747 86% 8,104 72% 1,092.9 0.001
Beta-blocker 21,421 53% 3,730 33% 1,340.0 0.001
Hospital procedures and tests
Intubation 1,984 5% 917 8% 179.6 0.001
Cardiac catheterization 17,058 42% 1,634 15% 2,872.0 0.001
PTCA during stay 7,046 17% 490 4% 1,193.0 0.001
CABG during stay 3,663 9% 220 2% 632.4 0.001
LVEF, %
Missing 11,194 28% 4,293 38% 479.2 0.001
,20 421 1% 370 3% 298.9 0.001
20–39 7,227 18% 3,047 27% 484.0 0.001
40–54 15,006 37% 2,709 24% 641.7 0.001
$55 6,776 17% 808 7% 633.4 0.001
Medications prescribed at discharge
ACE inhibitor 13,331 33% 4,664 42% 295.6 0.001
Warfarin 6,533 16% 1,852 16% 1.1 0.291
Aspirin 28,225 69% 6,007 54% 1,000.5 0.001
Insulin 3,766 9% 1,559 14% 203.4 0.001
Oral hypoglycemic 4,766 12% 1,369 12% 1.8 0.180
Bronchodilator 3,992 10% 1,518 14% 126.4 0.001
Beta-blocker 16,640 41% 2,534 23% 1,276.5 0.001
Calcium channel blocker 14,784 36% 3,813 34% 22.6 0.001
Antidepressant medication 2,094 5% 887 8% 122.4 0.001
ACE 5 angiotensin-converting enzyme; BUN 5 blood urea nitrogen; CABG 5 coronary artery bypass graft surgery; CHF 5 congestive heart failure; DBP 5 diastolic blood
pressure; LBBB 5 left bundle branch block; LVEF 5 left ventricular ejection fraction; PTCA 5 percutaneous transluminal coronary angioplasty; RBBB 5 right bundle branch
block; SBP 5 systolic blood pressure; WBC 5 white blood cell.
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with 22% among hospital survivors in our study. Both
studies identified age, ejection fraction and heart failure as
important predictors of mortality. Our study further iden-
tified the prognostic importance of comorbidity in these
patients, factors that may be less important in a younger
randomized trial population. The GUSTO investigators were
able to define a group with 1% mortality at one year, but we
could not identify a group with a risk of death that was ,7%.
This study is also distinct from the recently published
Predicting Risk of Death in Cardiac Disease Tool (PRE-
DICT) risk score in several ways (9). The PREDICT score
estimated the six-year death rate from information on
admission and discharge diagnoses of 6,134 patients aged 30
to 74 years at the time of their hospitalization. The
predictors included electrocardiographic variables, measures
of shock, age, and clinical history of angina, AMI or stroke.
Our study focused on one-year outcomes, which occurred at
a substantial rate in this national cohort of older Americans.
In addition, we used demographic and clinical information
from the hospitalization that was derived from chart review,
not billing codes. We also considered information about
functional status. In our score, several of these noncardiac
variables had substantial prognostic importance.
Model variables. The challenge for the clinician discharg-
ing a patient after an AMI is to distinguish the patients who
remain at higher risk from the many relatively low-risk
patients. Numerous tests have been developed to aid in this
process, but the assessment should start with clinical data
and an assessment of the ejection fraction. The clinical data
available for all patients and ejection fraction should be
obtained, aside from its prognostic value, because of its
importance in determining the use of angiotensin-
converting enzyme inhibitors. A highly predictive model
based on this information can guide the use of further
testing or interventions. Additional tests must be highly
sensitive and specific if they are to have incremental clinical
value beyond what is already available.
This study revealed some prognostic factors that are not
commonly included in studies of patients with an AMI.
Frailty, as indicated by decreased functional status (urinary
incontinence, inability to walk) and low body mass index
was also an important predictor of mortality. These character-
istics may indicate the absence of functional reserve and a
susceptibility to a large number of mortality risks. The geriat-
rics literature is replete with information about the relationship
of functional status with outcomes, but this information is
rarely collected and reported in cardiology studies despite the
high prevalence of cardiovascular disease in the elderly.
Several variables are conspicuous by their absence. Al-
though we do include variables that indicate a higher risk for
sudden arrhythmic events (e.g., LVEF, heart failure), there
are others that have been reported that we do not include
(e.g., size of infarction, anterior or Q-wave infarction,
ventricular ectopy). We also did not include any electrocardio-
graphic characteristics in the final model. All of these factors
may have prognostic value, but we particularly sought to
identify a small number of highly influential variables that
would have the best predictive value. We purposely did not
include all of the variables that were statistically significant.
Our risk index also does not include an assessment of the
extent of coronary disease or myocardium at risk. Our
findings do not undermine the conventional wisdom that
the severity of coronary disease and the amount of myocar-
Table 2. Study Logic (Inclusions and Exclusions)
Total sample 234,769
Exclusions*
Age ,65 years 17,593 (7.5%)
AMI not confirmed 31,186 (13.3%)
Transferred 75,981 (32.7%)
Repeat hospitalization† 23,773 (10.6%)
Hospital death 33,508 (14.3%)
Terminal illness 4,617 (2.0%)
Unverified death 204 (0.1%)
Study sample 103,164
Derivation sample 51,851 (50.3%)
Validation sample 51,313 (49.7%)
*Not mutually exclusive; †repeat hospitalization occurred in 22,187 patients.
AMI 5 acute myocardial infarction.
Table 3. Derived Model by Cox Regression Analysis (in Derivation Set)
Characteristics
Parameter
Estimate
Standard
Error
Wald Chi-
Square
P >
Chi-Square
Risk
Ratio
Lower
Limit
Upper
Limit
Age 75–84 years 0.4023 0.0238 286.06 0.0001 1.495 1.427 1.567
Age $85 years 0.6716 0.0271 612.72 0.0001 1.957 1.856 2.064
BMI missing 0.2190 0.0240 83.20 0.0001 1.245 1.188 1.305
BMI ,20 kg/m2 0.3609 0.0306 139.33 0.0001 1.435 1.351 1.523
BUN .40 mg/dl or highest creatinine .2.5 mg/dl 0.6658 0.0226 866.47 0.0001 1.946 1.862 2.034
Urinary incontinence or no urinary output 0.4683 0.0250 349.74 0.0001 1.597 1.521 1.678
Walks with assistance 0.3708 0.0220 285.18 0.0001 1.449 1.388 1.513
Unable to walk 0.7716 0.0350 486.30 0.0001 2.163 2.020 2.317
Peripheral vascular disease 0.3226 0.0264 148.92 0.0001 1.381 1.311 1.454
CHF/pulmonary edema or cardiomegaly 0.8040 0.0262 944.39 0.0001 2.234 2.123 2.352
LVEF missing 0.4962 0.0232 459.55 0.0001 1.642 1.570 1.719
LVEF ,20% 1.0592 0.0550 370.29 0.0001 2.884 2.589 3.213
LVEF 20%–39% 0.5595 0.0251 495.75 0.0001 1.750 1.666 1.838
BMI 5 body mass index; BUN 5 blood urea nitrogen; CHF 5 congestive heart failure; LVEF 5 left ventricular ejection fraction.
458 Krumholz et al. JACC Vol. 38, No. 2, 2001
One-Year Mortality After AMI August 2001:453–9
dial tissue at risk for recurrent ischemia have a major
influence on long-term prognosis. We demonstrate that
before employing either of the two major testing strategies
(noninvasive stress testing and cardiac catheterization),
physicians can estimate the risk of dying within one year
after discharge with reasonable accuracy.
Study limitations. In this study, we had an extensive list of
candidate variables for the models. Unfortunately, despite
information in the first electrocardiogram, we did not have
information about the presence of ST-segment depression,
though it is interesting that none of our electrocardiographic
variables strongly predicted one-year outcomes among pa-
tients who survived the hospitalization. Also, some of our
variables had missing values. We did not attempt to impute
values but did indicate that they were missing. Our second-
ary analyses did not suggest that our results were substan-
tially affected by the missing data.
Conclusions. We demonstrate that a simple risk model
can effectively stratify older patients by their risk of death
one year after discharge for AMI. The model has good
discriminant value and can be used to stratify patients into
three risk groups with mortality ranging from 7% to 49%.
Knowledge of risk in this contemporary cohort should
enhance clinical decision making with respect to further
diagnostic testing and intervention.
Reprint requests and correspondence: Dr. Harlan M. Krumholz,
Yale University School of Medicine, 333 Cedar Street, PO Box
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Table 4. Mortality by Risk Groups: Comparison of the Derivation and the Validation Samples
Risk Groups*
Derivation Sample Validation Sample Total
# of
Patients
% of
Events
# of
Patients
% of
Events
# of
Patients
% of
Events
Distribution
Low 20,032 40.13 19,648 39.76 39,680 39.90
Medium 20,987 42.04 20,694 41.87 41,681 42.00
High 8,903 17.83 9,080 18.37 17,983 18.10
Mortality
Low 1,459 7.28 1,433 7.29 2,892 7.29
Medium 4,982 23.74 4,926 23.80 9,908 23.77
High 4,407 49.50 4,436 48.85 8,843 49.17
Mortality or readmission
Low 9,425 47.05 9,402 47.85 18,827 47.45
Medium 13,372 63.72 13,312 64.33 26,684 64.02
High 6,997 78.59 7,081 77.98 14,078 78.29
Mortality or readmission for AMI
Low 2,783 13.89 2,821 14.36 5,604 14.12
Medium 6,603 31.46 6,631 32.04 13,234 31.75
High 4,878 54.79 4,931 54.31 9,809 54.55
*Risk groups were determined by the risk score: low risk (0–2), medium risk (3–5), high risk ($6).
AMI 5 acute myocardial infarction.
459JACC Vol. 38, No. 2, 2001 Krumholz et al.
August 2001:453–9 One-Year Mortality After AMI
